Study of KM-023 for healthy volunteers and Olmsted syndrome patients
Part of Skin clinical trials.
This trial tests a new medication, KM-023, first in healthy volunteers to check safety, and then in people with Olmsted syndrome (a rare skin condition causing thick, painful palms and soles). It aims to see if the drug is safe and helpful for those affected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: you need to be a non-smoker, not taking certain medicines, and have a body weight between 110 and 220 pounds.
- For Olmsted syndrome patients: you must have a confirmed diagnosis with a specific gene change (TRPV3 or PERP) and visible thick skin on palms and soles.
- Your medical condition should be stable for at least the past month.
- You must be willing to avoid certain treatments and follow the study schedule.
- Women who could become pregnant and men must use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication in healthy adults to see how safe it is and how the body handles it. It's an early-stage study, so participants help determine the right dose for future patients.
This study tests a new medicine called olomorasib in healthy volunteers to see how it works in the body depending on how it's taken. The goal is to find a better, safer way to give this medicine for future patients.
This trial tests whether the study drug KP-001 can help reduce symptoms like pain, fatigue, or bleeding caused by certain vascular malformations (abnormal blood vessel growths) that can't be surgically removed or haven't responded to other treatments. It's for people age 2 and older with specific conditions such as common venous malformations, lymphatic malformations, or KTS/CLOVES syndrome.
This study tests a new medicine called KS101 to see if it is safe and how it works in healthy people for the first time. It is a first-in-human trial, meaning this is the first time the drug is given to people, and your health will be closely monitored throughout.
This study tests a new medicine, KR23343, in healthy adults to see how the body handles it at different doses. It helps find the right dose and check for any early side effects.
This early-stage study tests a new experimental drug called LG-0317 in healthy volunteers to see if it is safe and how the body processes it. If you are healthy and meet the basic requirements, this trial may help advance a new treatment option.
Hear when a new Olmsted Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.